Creating EU-CTR compliant and patient-friendly lay language summaries (LLS)

Return to Insights Center

Related Insights

Blog

Breaking through complex regulations and science speak – thinking “patients first” in lay language summary development

Jun 22, 2021

Playbook

Streamlining success: How integrated evidence planning transforms asset development

Feb 27, 2025

Blog

Optimize your post-approval CMC change management in China with the ICH Q12 tool

Nov 24, 2025

Blog

Ensuring future success in a new market by delivering a robust safety database solution

Aug 4, 2023

Whitepaper

Advancing clinical development through innovative trial design

Nov 3, 2023

Blog

Assessing the need for comparative clinical trials in biosimilar development programs

Sep 21, 2023

Whitepaper

Scientific Validity Reports: a mandatory requirement for In Vitro Diagnostic Regulation (IVDR)

Sep 19, 2023

Article

Australia: The Regulatory and Reimbursement Environment

Aug 28, 2023

Whitepaper

Optimizing the Route to Regulatory Approval for a Novel Vaccine

Aug 18, 2023

Whitepaper

How to prepare for Policy 0070: Challenges and opportunities for clinical data publication in the EU

Jun 28, 2023

Article

The technologies that are reshaping biotherapeutics manufacturing, an EU perspective

Jul 6, 2023

Blog

Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market

Nov 13, 2023

Related Insights

Blog

Breaking through complex regulations and science speak – thinking “patients first” in lay language summary development

Jun 22, 2021

Playbook

Streamlining success: How integrated evidence planning transforms asset development

Feb 27, 2025

Blog

Optimize your post-approval CMC change management in China with the ICH Q12 tool

Nov 24, 2025

Blog

Ensuring future success in a new market by delivering a robust safety database solution

Aug 4, 2023

Whitepaper

Advancing clinical development through innovative trial design

Nov 3, 2023

Blog

Assessing the need for comparative clinical trials in biosimilar development programs

Sep 21, 2023

Show more